Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268782 | 1.00 | GPR119 (0.40) | GPR119HSD11B1JAK2JAK3PTK2 | |
| SCHEMBL22801916 | 0.90 | GPR119 (0.40) | GPR119HSD11B1JAK2JAK3PTK2 | |
| SCHEMBL22801958 | 0.90 | GPR119 (0.40) | GPR119HSD11B1JAK2JAK3PTK2 | |
| SCHEMBL22822839 | 0.90 | GPR119 (0.40) | GPR119HSD11B1JAK2JAK3PTK2 | |
| SCHEMBL22801944 | 0.89 | MAPT (0.38) | GPR119JAK2PDE10A | |
| SCHEMBL21285657 | 0.89 | MAPT (0.38) | GPR119JAK2PDE10A | |
| SCHEMBL22822830 | 0.89 | GPR119 (0.39) | GPR119HSD11B1JAK2JAK3PTK2 | |
| SCHEMBL21285489 | 0.86 | PDE10A (0.33) | PDE10A | |
| SCHEMBL21268780 | 0.85 | GPR119 (0.42) | GPR119HSD11B1JAK2JAK3PTK2 | |
| SCHEMBL22822764 | 0.85 | PDE10A (0.36) | HSD11B1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3527209-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB Biopharma SPRL (BE) | 2019-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | GPR119 388/4885HSD11B1 1156/4885JAK2 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.